< Back to scientific publications

Magazine

Use of Plerixafor in Predicted and ProvenPoorMobilizer( according to GITMO criteria). Experience of Tor Vergata University Polyclinic.

Authors: Massimiliano Postorino, Alessandro Lanti, Eleonora Florelli, Angelo Salvatore Ferraro, Oana Marilena Chiuru,Raffaella Massarelli, Luca Franceschini, Giorgia Guiducci,Provenzano I., Livio Pupo, Anna Giulia Zizzari, GaspareAdorno, Maria Cantonetti, Giancarlo Isacchi and Sergio Amadori. (2012).

Date: 2012

Scope of interest: Hematology/Transfusion Medicine




You may also be interested in:

Report/Poster of Convention/Congress Act

Use of hyperimmune plasma for compassionate use in patients with Marginal Non-Hodgkin Lymphoma persistently positive for SARS-Cov-2 infection

Authors: D’Amico C. et al.

Date: 2022

Scope of interest: Transfusion Medicine


Read details
Magazine 11.26

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study.

Authors: Lattanzi S, Canafoglia L, Canevini MP, Casciato S, Cerulli Irelli E, Chiesa V, Dainese F, De Maria G, Didato G, Di Gennaro G, Falcicchio G, Fanella M, Ferlazzo E, Gangitano M, La Neve A, Mecarelli O, Montalenti E, Morano A, Piazza F, Pizzanelli C, Pulitano P, Ranzato F, Rosati E, Tassi L, Di Bonaventura C; BRIVAracetam add-on First Italian‚oRk Study (BRIVAFIRST) Group.

Date: 2022

Scope of interest: Epilepsy


Read details
Report/Poster of Convention/Congress Act

Poor Mobilizer” with myeloma or lymphoma. Experience of the”Tor Vergata”Polyclinic Stem Cell Collection Center

Authors: Fiorelli E., Lanti A., Ferraro A.S., D’Alessandro E., Chiru O.M., Del Proposto G., Cerrone P., De Angelis L., Guiducci G., Zinno F., Adorno G., Isacchi G., “ Plerixafor in association with G-CSF as a mobilization regimen in patients

Date: 2014

Scope of interest: Clinical pathology


Read details